FINWIRES · TerminalLIVE
FINWIRES

NSE:ZYDUSLIFE

6 stories mentioning NSE:ZYDUSLIFE

Every FINWIRES story that references NSE:ZYDUSLIFE, newest first.

Asia

Zydus Lifesciences Unit Secures Reduction in GST Tax Demands

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) said appellate authorities in Chhattisgarh, India, have substantially reduced tax demands and penalties imposed on its wholly owned subsidiary, Zydus Healthcare, in input tax credit (ITC) cases for financial years 2018-19 and 2019-20, according to a Tuesday filing on Indian bourses.For the financial year 2018-19, demand was reduced to 24,000 rupees from 2.9 million rupees, including penalty, the company said in the filing.For the financial year 2019-20, demand was cut to 20,000 rupees from around 1.3 million rupees, including penalty, it added.The relief was granted through orders passed by the Appellate Additional Commissioner of State, Chhattisgarh, the company said.Shares of Zydus Lifesciences rose 1% in recent trade.

BOM:532321NSE:ZYDUSLIFE
Asia

Zydus Lifesciences Receives USFDA Warning Letter for Baddi Facility

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) said it received a warning letter from the U.S. Food and Drug Administration related to its formulations manufacturing facility in Baddi, Himachal Pradesh, according to a Wednesday filing on Indian bourses.The warning letter was issued in response to a records request under the Federal Food, Drug, and Cosmetic Act, the company said. It relates to observations regarding the use of purified talc that did not meet current U.S. Pharmacopeia requirements.Zydus said the letter is not linked to an on-site inspection and does not affect current operations or supplies from the facility.

BOM:532321NSE:ZYDUSLIFE
Asia

Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,200 From INR1,100, Keeps at Buy

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has an average rating of overweight and mean price target of 1,031.39 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

BOM:532321NSE:ZYDUSLIFE
Asia

Indian Equities Jump on Wednesday as US-Iran Deal Hopes Lift Sentiment

Indian benchmark indices ended sharply higher on Wednesday as reports of a possible U.S.-Iran deal supported global risk sentiment.The BSE Sensex rose 940.73 points, or 1.22%, to close at 77,958.52, while the NSE Nifty 50 gained 298.15 points, or 1.24%, to settle at 24,330.95.Markets advanced on expectations that the U.S. and Iran may be close to resolving their conflict, which had pushed energy prices higher in recent sessions. Hopes of easing geopolitical risks supported sentiment and helped drive broad-based buying.In economic news, Services activity in Indian strengthened in April, with the HSBC India Services PMI rising to 58.8 from 57.5, supported by firm domestic demand and e-commerce growth. New orders saw the fastest expansion in five months, aided by pricing strategies and demand for logistics and relocation services. However, export growth slowed to a five-month low amid Middle East tensions and weak tourism.In earnings news, Aditya Birla Real Estate (NSE:ABREL, BOM:500040) gained nearly 5% after reporting a profit of 108.4 million rupees in Q4, compared with a loss of 1.31 billion rupees a year earlier, according to a filing. Revenue from operations declined to 981.9 million rupees from 4.08 billion rupees.Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) rose over 3% after receiving seven observations from the US FDA following an inspection of its Ahmedabad facility, according to a Wednesday filing.

^BSENifty 50BOM:500040BOM:532321NSE:ABRELNSE:ZYDUSLIFE
Asia

Zydus Gets Seven Observations from US FDA After Ahmedabad, India Unit Inspection; Shares Up 3%

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) received seven observations from the US Food and Drug Administration (US FDA) following the inspection of its Unit 9 facility located at Zydus Biotech Park in Ahmedabad, India, according to a Wednesday filing to the India stock exchanges.The regulator inspected the Ahmedabad unit from April 27 to May 5.The company plans to closely work with the USFDA for work on resolving the observations expeditiously.The company's shares were up nearly 3% in recent trade.

BOM:532321NSE:ZYDUSLIFE
Asia

Zydus Lifesciences Gets US FDA Approval for Oncology Injectable Manufacturing Site

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has received the establishment inspection report and approval letter from the US Food and Drug Administration for its oncology injectable manufacturing site in Ahmedabad, India.The US FDA conducted a pre-approval inspection at the facility in November 2025 in relation to the new isolator injectable line, according to a Thursday filing to the Indian stock exchanges.

BOM:532321NSE:ZYDUSLIFE